Related references
Note: Only part of the references are listed.Pooled historical MRI data as a basis for research in multiple sclerosis - a statistical evaluation
S. Schach et al.
MULTIPLE SCLEROSIS (2007)
Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis
Federica Agosta et al.
BRAIN (2006)
Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis
P. J. Young et al.
NEUROLOGY (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Predictors of relapse rate in MS clinical trials
U Held et al.
NEUROLOGY (2005)
The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic era
HF McFarland et al.
MULTIPLE SCLEROSIS JOURNAL (2005)
Why most published research findings are false
JPA Ioannidis
PLOS MEDICINE (2005)
Surrogate endpoints and FDA's accelerated approval process
TR Fleming
HEALTH AFFAIRS (2005)
MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-lb
MP Sormani et al.
NEUROLOGY (2003)
A controlled trial of natalizumab for relapsing multiple sclerosis.
DH Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
The role of MRI as a surrogate outcome measure in multiple sclerosis
HF McFarland et al.
MULTIPLE SCLEROSIS JOURNAL (2002)
Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS
PD Molyneux et al.
NEUROLOGY (2001)
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
G Comi et al.
ANNALS OF NEUROLOGY (2001)
Share Paper
